Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

595 trials

NCT05945524
Recruiting
Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination
Not applicable · France · 18 sites
Registry update: 10 Apr 2025
NCT06066346
Recruiting
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Phase 2 · United States · 7 sites
Registry update: 4 Mar 2026
NCT05969860
Recruiting
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · United States · 2 sites
Registry update: 6 Nov 2026
NCT06055894
Recruiting
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
Not applicable · United States · 7 sites
Registry update: 5 Oct 2026
NCT05730036
Recruiting
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Phase 3 · Australia, Belgium, Brazil, Canada, Chile, Germany, Spain, France, United Kingdom, Israel, Italy, Japan, South Korea, Netherlands, Poland, Singapore, Taiwan, United States · 150 sites
Registry update: 6 Nov 2026
Conflicting statuses (updated in the registry within the last month)
NCT05956457
Recruiting
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
Not applicable · United States · 1 site
Registry update: 20 Apr 2025
NCT05837884
Recruiting
Predicting Progression of Developing Myeloma in a High-Risk Screened Population and General Population
Not applicable · Israel · 4 sites
Registry update: 11 Aug 2026
NCT07205523
Recruiting
High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
Not applicable · China · 1 site
Registry update: 3 Oct 2025
NCT05866757
Recruiting
Discontinuation Study
Not applicable · Ireland · 1 site
Registry update: 4 Mar 2026
NCT05597345
Recruiting
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Phase 2 · United States · 1 site
Registry update: 10 Feb 2025
NCT06541860
Recruiting
DAratumumab and REvlimid REfractory MM
Not applicable · Italy · 1 site
Registry update: 7 Aug 2024
NCT05776979
Recruiting
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
Phase 2 · United States · 1 site
Registry update: 20 Oct 2026
NCT05927571
Recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Phase 1 · Australia, Israel, South Korea · 14 sites
Registry update: 5 Nov 2026
NCT05850234
Recruiting
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Phase 1/2 · United States · 34 sites
Registry update: 8 Oct 2026
NCT05974150
Recruiting
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
Not applicable · United States · 7 sites
Registry update: 30 Oct 2026
NCT05642884
Recruiting
Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
Not applicable · United States · 1 site
Registry update: 24 Dec 2025
NCT05932680
Recruiting
Limited-duration Teclistamab
Phase 2 · United States · 5 sites
Registry update: 5 Oct 2026
NCT06045091
Recruiting
To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
Early phase 1 · China · 1 site
Registry update: 21 Sept 2023
NCT05965115
Recruiting
The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
Not applicable · China · 1 site
Registry update: 1 Aug 2023
NCT05706766
Recruiting
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Not applicable · United States · 1 site
Registry update: 22 Jan 2026

Ordered by registry start date. Freshness and sponsorship never change the order.